Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK3 | O43781 | 5/20 | 0.79 |
| ▸ | GSK3B | P49841 | 3/20 | 0.78 |
| ▸ | CLK1 | P49759 | 2/20 | 0.78 |
| ▸ | CLK3 | P49761 | 2/20 | 0.78 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.78 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.78 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.78 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.78 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.78 |
| ▸ | CLK2 | P49760 | 1/20 | 0.78 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.78 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.61 |
| ▸ | PIM1 | P11309 | 1/20 | 0.61 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.61 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.61 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.61 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.61 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.61 |
| ▸ | MYLK2 | Q9H1R3 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3393455 | 1.00 | DYRK3 (0.79) | DYRK3GSK3BCLK1CLK3DYRK1A | |
| SCHEMBL2811101 | 0.99 | DYRK3 (0.80) | DYRK3GSK3BCLK1CLK3DYRK1A | |
| SCHEMBL13078147 | 0.99 | DYRK3 (0.80) | DYRK3GSK3BCLK1CLK3DYRK1A | |
| SCHEMBL2811103 | 0.99 | DYRK3 (0.80) | DYRK3GSK3BCLK1CLK3DYRK1A | |
| SCHEMBL13041813 | 0.99 | DYRK3 (0.80) | DYRK3GSK3BCLK1CLK3DYRK1A | |
| SCHEMBL2786117 | 0.88 | DYRK3 (1.00) | DYRK3GSK3BCLK1CLK3DYRK1A | |
| SCHEMBL2786118 | 0.88 | DYRK3 (1.00) | DYRK3GSK3BCLK1CLK3DYRK1A | |
| SCHEMBL13196821 | 0.88 | DYRK3 (1.00) | DYRK3GSK3BCLK1CLK3DYRK1A | |
| SCHEMBL13041807 | 0.88 | DYRK3 (1.00) | DYRK3GSK3BCLK1CLK3DYRK1A | |
| SCHEMBL13041788 | 0.88 | DYRK3 (1.00) | DYRK3GSK3BCLK1CLK3DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100286041-A1 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | SMITHKLINE BEECHAM CORPORATION | 2010-11-11 | — | — | US | disclosed |
| US-7674792-B2 | 5(Z)-5-(6-quinoxalinylmethylidene)-2-[2,6-dichlorophenyl)amino]-1,3-thiazol-4(5H)-one | GLAXOSMITHKLINE LLC (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1888531-A4 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-Ý(2,6-DICHLOROPHENYL)AMINO¨-1,3-THIAZOL-4(5H)-ONE | SMITHKLINE BEECHAM CORP (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080194466-A1 | (5Z)-5-(6-Quinoxalinylmethylidene)-2-[(2,4,6-Trichlorophenyl)Amino]-1,3-Thiazol-4(5H)-One | SMITHKLINE BEECHAM CORPORATION | 2008-08-14 | — | — | US | disclosed |
| EP-1888531-A2 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-Ý(2,6-DICHLOROPHENYL)AMINO¨-1,3-THIAZOL-4(5H)-ONE | Smithkline Beecham Corporation (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1888557-A2 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-Ý(2,4,6-TRICHLOROPHENYL)AMINO¨-1,3-THIAZOL-4(5H)-ONE | Smithkline Beecham Corporation (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070179144-A1 | for treatment of deficiencies in hematopoietic cells | GLAXOSMITHKLINE LLC | 2007-08-02 | — | — | US | disclosed |
| WO-2006135712-A2 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006133381-A2 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,4,6-TRICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286041-A1 | (5Z)-5-(6-QUINOXALINYLMETHYLIDENE)-2-[(2,6-DICHLOROPHENYL)AMINO]-1,3-THIAZOL-4(5H)-ONE | HYPK, HIPK3, HIPK1 | DYRK3 44/4885GSK3B 842/4885CLK1 175/4885 |
| US-20070179144-A1 | for treatment of deficiencies in hematopoietic cells | HCLS1, HIPK3, HYPK | DYRK3 423/4885GSK3B 1486/4885CLK1 523/4885 |
| US-20080194466-A1 | (5Z)-5-(6-Quinoxalinylmethylidene)-2-[(2,4,6-Trichlorophenyl)Amino]-1,3-Thiazol-4(5H)-One | HYPK, HIPK3, HIPK1 | DYRK3 101/4885GSK3B 995/4885CLK1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.